Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

What the trial testedas reported · 13,165 people · 2026

Not counted

−16%−21% to −10%

24 in 100 instead of 27

Bigger than 4 in 10 on the map

As reported

HR 0.84, 95% CI 0.79–0.90

the abstract, start to end

… patients (27.4%; hazard ratio [HR], 0.84; 95% CI, 0.79-0.90; P < .001).

← favours treatmentfavours comparator →

could be chance

Kidney outcomes

HR 0.840.79–0.90

GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsKidney outcomes

1 / 3

2026

this papercites it